Top Markets
Coin of the day
Palvella Therapeutics, Inc. Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

PVLA
Rank in Stocks #6138
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company... Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Share Price
$154.04
Market Cap
$2.21B
Change (1 day)
-0.19%
Change (1 year)
172.88%
Country
US
Trade Palvella Therapeutics, Inc. (PVLA)

Category

Dividend yield history for Palvella Therapeutics, Inc. (PVLA)
Palvella Therapeutics, Inc. (stock symbol: PVLA) dividend yield (TTM) as of 2026: 0
Average dividend yield, last 5 years : 0.00%
Dividend yield history for Palvella Therapeutics, Inc. (PVLA) from 2026 to 2026
Dividend Yield at the end of each year (TTM)
Year Dividend Yield Change
Not enough data for the provided dates.
Dividend yields (TTM) for similar companies or competitors
Company Dividend Yield Country
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH